{"doi":"10.1016\/S0163-4453(96)80019-3","coreId":"210790","oai":"oai:eprints.lse.ac.uk:22452","identifiers":["oai:eprints.lse.ac.uk:22452","10.1016\/S0163-4453(96)80019-3"],"title":"An economic evaluation of universal vaccination against Hepatitis B virus","authors":["McGuire, Alistair","Fenn, Paul","Gray, Alistair"],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"1996-05","abstract":"This report presents the results of an economic evaluation utilizing U.K. data, into a vaccination programme against Hepatitis B using a genetically engineered, yeast-derived vaccine, Engerix B. Cost-effectiveness ratios were calculated for four different programmes: an infant vaccination programme; a child vaccination programme; an adolescent vaccination programme; and a combined child and adolescent programme. For each programme, the number of annual cohorts vaccinated was varied from 1 to 25. The outcome was defined as incremental life years gained, and the results are reported as costs per incremental life-year gained. Benefits were calculated in both undiscounted and discounted forms. All costs were discounted. The discount rate used was 6%. All major epidemiological and cost assumptions were subjected to a sensitivity analysis. Baseline results with benefits discounted range from \u00a3188 015 to \u00a3301 365 per life year gained, depending on the duration of programme and vaccination strategy. With benefits undiscounted, the comparable range is from \u00a35234 to \u00a313 034","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":"Elsevier","rawRecordXml":"<record><header><identifier>\n    \n    \n      oai:eprints.lse.ac.uk:22452<\/identifier><datestamp>\n      2010-10-01T09:20:26Z<\/datestamp><setSpec>\n      74797065733D4445505453:4C53452D5341<\/setSpec><setSpec>\n      74797065733D43454E54524553:4C53455F52435F3839<\/setSpec><\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:relation>\n    \n      \n        http:\/\/eprints.lse.ac.uk\/22452\/<\/dc:relation><dc:title>\n        An economic evaluation of universal vaccination against Hepatitis B virus<\/dc:title><dc:creator>\n        McGuire, Alistair<\/dc:creator><dc:creator>\n        Fenn, Paul<\/dc:creator><dc:creator>\n        Gray, Alistair<\/dc:creator><dc:subject>\n        RA Public aspects of medicine<\/dc:subject><dc:description>\n        This report presents the results of an economic evaluation utilizing U.K. data, into a vaccination programme against Hepatitis B using a genetically engineered, yeast-derived vaccine, Engerix B. Cost-effectiveness ratios were calculated for four different programmes: an infant vaccination programme; a child vaccination programme; an adolescent vaccination programme; and a combined child and adolescent programme. For each programme, the number of annual cohorts vaccinated was varied from 1 to 25. The outcome was defined as incremental life years gained, and the results are reported as costs per incremental life-year gained. Benefits were calculated in both undiscounted and discounted forms. All costs were discounted. The discount rate used was 6%. All major epidemiological and cost assumptions were subjected to a sensitivity analysis. Baseline results with benefits discounted range from \u00a3188 015 to \u00a3301 365 per life year gained, depending on the duration of programme and vaccination strategy. With benefits undiscounted, the comparable range is from \u00a35234 to \u00a313 034.<\/dc:description><dc:publisher>\n        Elsevier<\/dc:publisher><dc:date>\n        1996-05<\/dc:date><dc:type>\n        Article<\/dc:type><dc:type>\n        NonPeerReviewed<\/dc:type><dc:identifier>\n          McGuire, Alistair and Fenn, Paul and Gray, Alistair  (1996) An economic evaluation of universal vaccination against Hepatitis B virus.  Journal of Infection, 32 (3).  pp. 197-204.  ISSN 0163-4453     <\/dc:identifier><dc:relation>\n        http:\/\/www.sciencedirect.com\/science\/journal\/01634453<\/dc:relation><dc:relation>\n        10.1016\/S0163-4453(96)80019-3<\/dc:relation><\/oai_dc:dc><\/metadata><\/record>","journals":null,"language":null,"relations":["http:\/\/eprints.lse.ac.uk\/22452\/","http:\/\/www.sciencedirect.com\/science\/journal\/01634453","10.1016\/S0163-4453(96)80019-3"],"year":1996,"topics":["RA Public aspects of medicine"],"subject":["Article","NonPeerReviewed"],"fullText":null}